CHMP recommends EU approval of Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors

Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ®(emicizumab) for routine prophylaxis of bleeding episodes in adults and children with severe haemophilia A (congenital factor VIII deficiency, FVIII
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news